XOMA (XOMA) Projected to Post Earnings on Thursday

XOMA (NASDAQ:XOMA - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect XOMA to post earnings of ($0.26) per share and revenue of $6.75 million for the quarter.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. On average, analysts expect XOMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

XOMA Stock Performance

XOMA stock traded down $0.62 during midday trading on Tuesday, hitting $23.35. The company's stock had a trading volume of 7,032 shares, compared to its average volume of 28,002. The company has a 50-day moving average price of $21.32 and a two-hundred day moving average price of $25.67. XOMA has a 1-year low of $18.35 and a 1-year high of $35.00. The company has a market cap of $279.04 million, a price-to-earnings ratio of -6.71 and a beta of 0.89. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Friday, April 11th. Benchmark initiated coverage on XOMA in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $104.00 price target on shares of XOMA in a report on Friday, March 28th.

Insider Activity at XOMA

In other XOMA news, CIO Bradley Sitko purchased 4,134 shares of the firm's stock in a transaction on Friday, March 21st. The stock was purchased at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the transaction, the executive now owns 10,484 shares in the company, valued at $250,462.76. The trade was a 65.10 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Joseph M. Limber purchased 17,935 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were acquired at an average price of $25.24 per share, for a total transaction of $452,679.40. Following the acquisition, the director now owns 16,524 shares of the company's stock, valued at $417,065.76. This trade represents a -1,271.08 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 29,312 shares of company stock valued at $735,061 in the last quarter. Insiders own 7.20% of the company's stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.